Tag: research

Is Antidepressant Withdrawal Overhyped? What the Evidence Really Says

In my clinical practice, I’ve often found myself scratching my head over the narrative surrounding antidepressant withdrawal.

I’m not denying that withdrawal is real—it is. And for a small subset of patients, it can be quite distressing. But what I am saying is this: it’s not nearly as common, dramatic, or dangerous as some online circles and sensational stories would have you believe.

I’ve seen countless patients abruptly stop antidepressants and experience no withdrawal symptoms. I’ve also aggressively tapered antidepressants in patients with bipolar disorder to prevent mood destabilization—again, with little to no evidence of withdrawal. This isn’t a one-off observation. It’s a consistent clinical pattern I’ve noted for years. So, I asked myself: What does the data actually say?

The Evidence

A 2024 meta-analysis published in JAMA Psychiatry examined 49 randomized controlled trials and finally gave us some clarity.

The results?
✅ People discontinuing antidepressants reported on average just one more symptom than those who either continued medication or discontinued a placebo.
✅ The most commonly reported symptoms in the first two weeks were dizziness, nausea, vertigo, and nervousness—exactly what I’ve seen clinically.
✅ Critically, the average number of symptoms fell below the threshold for what’s considered a clinically significant discontinuation syndrome.
✅ There was no link between discontinuation and worsening depression, suggesting that if mood symptoms return, it’s likely a relapse—not withdrawal.

Why This Matters

There are vocal groups online—often with clear anti-psychiatry agendas—who focus exclusively on rare, severe cases of withdrawal and present them as the norm. The goal is simple: to scare people away from psychiatry and evidence-based treatment using emotional testimonials instead of clinical reality.

Let’s be honest—those cases do exist, but they are not representative of what most patients experience.

As clinicians, we should remain cautious and responsible. Yes, we should taper medications thoughtfully. Yes, we should prepare patients for the possibility of withdrawal symptoms. But we also shouldn’t scare them into avoiding treatment—or make them feel trapped on medications for life.

Bottom Line

Antidepressant withdrawal can happen. It can be uncomfortable. But it’s rarely severe and almost never dangerous. The fear around it has been overstated by those with an ax to grind. We owe it to our patients to treat based on evidence, not anecdotes.

0

Understanding Psychiatry: Science vs. Skepticism

🧠 “Psychiatry is a scam.” “Big Pharma controls your brain.” “Mental illness isn’t real.”

You’ve heard the takes. Now here’s the truth.

In my new article for Psychiatric Times, I dive headfirst into the controversy:
👉 Understanding Psychiatry: Navigating Skepticism and Science
https://www.psychiatrictimes.com/view/understanding-psychiatry-navigating-skepticism-and-science

I don’t dodge the hard questions—about overmedication, broken trust, and bad science—but I also push back against lazy anti-psychiatry takes that ignore the very real suffering of patients.

If you care about the future of mental health care, this one’s worth your time.

0

New JAMA Study Challenges Previous Concerns About Valproate and Paternal Risk

What we thought we knew may not hold up under scrutiny.

A recent JAMA Psychiatry study titled “Disorders and Paternal Use of Valproate During Spermatogenesis” has delivered surprising news:

There was no increased risk of neurodevelopmental disorders in children whose fathers were taking valproic acid around the time of conception.

This finding directly challenges earlier observational data that suggested a possible link, leading to cautionary guidance against prescribing valproate to men of reproductive age. But now, with a large, well-conducted study showing no signal of harm, we’re left reconsidering that initial recommendation.

As clinicians, we must remember:
🔍 Association is not causation.
🚧 Observational studies, while valuable, can mislead when confounding variables aren’t fully accounted for.
📚 Evidence evolves—and so must our clinical guidance.

This study not only impacts how we think about valproate use in men but also serves as a critical reminder about the limits of inference from non-randomized data.

👉 For patients with bipolar disorder or epilepsy who benefit from valproate, this offers some reassurance. We may not need to withhold an effective treatment based on unconfirmed reproductive risks.

📌 Bottom line: Always be skeptical. Always be curious. Always be willing to revise your practice when the data say it’s time.

link to the study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2834363

0

ARISE Study Phase 3 Results: Understanding Xanomeline’s Setback

What Was the ARISE Study?

The ARISE trial was a Phase 3 clinical study evaluating Cobenfy — a combination of xanomeline (a muscarinic receptor agonist) and trospium chloride (a peripheral anticholinergic) — as an adjunctive treatment for adults with schizophrenia who continued to experience symptoms despite taking an atypical antipsychotic.

What Is a Primary Endpoint, and Why Does It Matter?

In clinical trials, the primary endpoint is the most important outcome researchers are trying to affect — it’s how a drug’s success or failure is officially judged.
In ARISE, the primary endpoint measured the change in symptom severity compared to placebo using a standardized scale for schizophrenia. Meeting this endpoint would have demonstrated clear, statistically significant symptom improvement attributable to Cobenfy.

The Outcome: No Statistically Significant Benefit

According to topline results, Cobenfy did not show a statistically significant improvement compared to placebo when added to atypical antipsychotics. This means the observed difference could have been due to chance and did not meet the pre-set threshold for success.

However, Cobenfy did show a numerical improvement — the group receiving the drug combination performed betterthan placebo in symptom reduction, just not to a statistically convincing degree.

Could Anticholinergic Effects Be to Blame?

One possible explanation for this outcome lies in the mechanism of action of both Cobenfy and many commonly used atypical antipsychotics.

  • Xanomeline is designed to activate muscarinic receptors in the brain (specifically M1 and M4), which may help regulate dopamine and reduce psychosis.
  • But many atypical antipsychotics — like olanzapine, clozapine, and quetiapine — also have anticholinergic properties, meaning they block these same receptors.

This sets up a pharmacological tug-of-war: Cobenfy tries to stimulate muscarinic activity, while the background antipsychotic may be dampening it. This conflict could blunt the therapeutic signal, explaining why the benefit didn’t reach statistical significance.

What This Means for the Future

The failure to meet the primary endpoint is a setback, but not the end of the road. The numerical improvements suggest a potential signal, and with refined trial design — perhaps using background medications with lower anticholinergic load — future studies may better reveal Cobenfy’s potential.

Additionally, this trial underscores the importance of considering mechanism compatibility in combination therapies. It’s not just about adding drugs — it’s about how they interact at the receptor level.

Conclusion

While the ARISE study didn’t deliver the result many hoped for, it raised critical questions that will shape future research. A deeper understanding of anticholinergic burden, drug synergy, and precision pharmacology is essential as we continue the search for more effective treatments for schizophrenia.

0

💊 Methylene Blue: Science-Based Hope or Hype in a Bottle? 💙

As someone who supports thoughtful use of complementary and alternative medicine, I absolutely believe that compounds like SAMe or St. John’s Wort can offer meaningful benefits—when used appropriately and supported by evidence. But with the rise of anti-aging influencers, we’re seeing a familiar pattern: mechanistically promising compounds getting pushed far ahead of the science.

Methylene Blue is a perfect example.

🧬 Mechanistic appeal:

  • Enhances mitochondrial respiration
  • Acts as a redox mediator to reduce oxidative stress
  • May support autophagy and protein homeostasis
  • Studied for cognitive enhancement and neuroprotection

Sounds great on paper—and some early research is encouraging. But…

⚠️ Here’s the caution:

  • Most data is from animal studies or in vitro experiments
  • Human trials for cognitive or anti-aging outcomes are small, inconsistent, and early-stage
  • Long-term safety at “biohacker” doses remains largely untested

Many people are understandably drawn to the promise of longer, healthier lives, but often at the cost of embracing interventions before we truly understand their risks, benefits, or limitations.

Even if the science makes theoretical sense, biology doesn’t always behave the way our models predict.

Let’s stay open—but also skeptical. Not everything that sounds too good to be true ends up being true.

0

RFK Jr. Claims He’ll Identify the Cause of Autism by September

In a bold statement this week, Robert F. Kennedy Jr. announced that he will reveal the definitive cause of autism by September. Kennedy, a longtime critic of childhood vaccine programs, did not provide specific scientific details or a research plan, but implied that his administration would prioritize transparency and independent investigations into the condition’s origins.

The claim has sparked immediate controversy. Autism is a complex neurodevelopmental condition with a strong genetic foundation and a wide range of potential environmental influences—none of which have yielded a singular, definitive cause. The scientific consensus, built over decades of rigorous research, continues to support a multifactorial model rather than a simplistic explanation.

Many highly intelligent and dedicated scientists have spent years studying autism without identifying a single, unifying cause. One of the recurring issues that arises when politics intersects with science is a resistance to the idea that these are nuanced, multifaceted conditions. It’s not the most satisfying explanation—but it is consistent with the best evidence we have. My fear is that this type of investigation, under political pressure, could prematurely identify a false causal agent—such as vaccines—and reignite a harmful narrative that has already been thoroughly debunked.

Kennedy’s history of promoting vaccine-autism links adds further concern. The CDC, WHO, and a vast body of peer-reviewed research have all concluded there is no credible evidence connecting vaccines to autism. Suggesting otherwise not only undermines public trust in science and medicine—it risks the health of entire communities by fueling vaccine hesitancy.

For families and individuals affected by autism, the promise of discovering its origins is understandably compelling. But it’s critical that we approach that pursuit with scientific integrity, not political expediency.

0

🚨 New Study Links Antidepressant Use to Significant Weight Gain Over 6 Years! 

A recent study published in Frontiers in Psychiatry reveals that individuals using antidepressants experienced notable weight gain over a six-year period.​

Key Findings:

  • Increased Weight Gain:​
    • Participants who used antidepressants showed an average weight increase of approximately 2% of their baseline body weight compared to non-users.​
  • Higher Obesity Risk:​
    • Those without obesity at the study’s start had double the risk of becoming obese if they used antidepressants throughout the six years.​

Implications:

With the widespread use of antidepressants and the global obesity epidemic, integrating weight management and metabolic monitoring into depression treatment plans is crucial.​

link: https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1464898/full

0

Olanzapine vs. Quetiapine for Stimulant Psychosis: Is One the Clear Winner?

There is limited high-quality randomized controlled trial (RCT) evidence specifically comparing Zyprexa (olanzapine) or Seroquel (quetiapine) for the treatment of stimulant-induced psychosis (SIP), including cocaine-induced psychosis. However, some RCTs and observational studies provide useful insights:

Olanzapine (Zyprexa)

  • RCT Evidence:
    • A 2022 meta-analysis of antipsychotic treatments for stimulant-induced psychosis included olanzapine and found it to be effective in reducing positive psychotic symptoms, often comparable to haloperidol but with a better side effect profile (less extrapyramidal symptoms) 11.
    • A double-blind RCT comparing olanzapine vs. haloperidol in methamphetamine-induced psychosisfound that both were effective at reducing PANSS (Positive and Negative Syndrome Scale) scores, but olanzapine was associated with better tolerability 22.
    • Another RCT in methamphetamine-induced psychosis compared olanzapine and risperidone, showing similar efficacy but better tolerability with olanzapine 33.

Quetiapine (Seroquel)

  • RCT Evidence:
    • A small RCT in methamphetamine-induced psychosis found that quetiapine was effective but tended to require higher doses to achieve symptom resolution 44.
    • A retrospective study on cocaine-induced psychosis suggested that quetiapine may help reduce symptoms, but data is weaker compared to olanzapine or risperidone 55.
    • Quetiapine has also been studied as an option for reducing cocaine cravings, but results are mixed and it is generally less preferred for acute agitation compared to faster-acting options like olanzapine.

Head-to-Head Comparison

There is no direct RCT comparing olanzapine vs. quetiapine for stimulant-induced psychosis, but based on available data:

  • Olanzapine is generally preferred for acute agitation and psychosis because of its faster onset and greater D2 blockade.
  • Quetiapine may be useful in milder cases or for individuals needing sedation, but higher doses are often required.

Clinical Implications

  • For acute stimulant-induced psychosis, olanzapine (5–10 mg IM or PO) is a common first-line option due to rapid onset and favorable side effect profile.
  • Quetiapine (200–400 mg PO) can be considered, particularly for patients needing sedation or those with comorbid conditions like bipolar disorder.
  • Other antipsychotics with strong evidence include risperidone and haloperidol (though the latter has more extrapyramidal risk).

After reviewing the available literature, direct randomized controlled trials (RCTs) comparing olanzapine (Zyprexa) and quetiapine (Seroquel) for stimulant-induced psychosis (SIP), including cocaine-induced psychosis, remain scarce. However, some studies provide relevant insights:

Olanzapine (Zyprexa):

  • Efficacy: A randomized, double-blind trial compared olanzapine and haloperidol in patients with amphetamine-induced psychosis. Both medications effectively improved psychotic symptoms in the short term, with olanzapine showing a faster onset of action.

Quetiapine (Seroquel):

  • Efficacy: A double-blind RCT compared haloperidol and quetiapine for methamphetamine-induced psychosis. While both medications reduced psychotic symptoms, quetiapine appeared to have a more favorable profile in reducing certain symptoms over time. 

Indirect Comparisons:

  • First-Episode Psychosis: A 52-week randomized, double-blind study evaluated olanzapine, quetiapine, and risperidone in early psychosis patients. All three antipsychotics demonstrated comparable effectiveness, as indicated by similar rates of treatment discontinuation.

Conclusion:

While direct RCT evidence comparing olanzapine and quetiapine specifically for stimulant-induced psychosis is limited, existing studies suggest that both medications are effective in managing such conditions. Olanzapine may offer a faster onset of symptom relief, whereas quetiapine might present a more favorable side effect profile. Clinical decisions should be individualized, considering factors such as patient history, specific symptomatology, and potential side effects.

0

Semaglutide (#Ozempic / #Wegovy) Reduced Alcohol & Nicotine Use in a First-of-Its-Kind RCT

📉 In a randomized trial with 48 patients diagnosed with #AlcoholUseDisorder, semaglutide significantly lowered alcohol intake in a controlled lab setting.

🚬 Interestingly, nicotine consumption also decreased.

💉 Low doses (0.25-1 mg/week) were used over 9 weeks—much lower than standard obesity or diabetes dosing.

🔬 More research is needed, but this adds to growing evidence that GLP-1 agonists may impact addictive behaviors.

Link to article: https://pubmed.ncbi.nlm.nih.gov/39937469/

0

🚨 Double Trouble? The Evidence on Combining Z-Drugs & Benzos 💊⚡

If you live long enough, you’ll see some crazy stuff 🤯. I believe in the art of psychopharmacology 🎨💊, and I’m a gunslinger who enjoys pushing the limits 🔫—but some things are just plain nuts. Buckle up for this one… 🚀⚡

There is limited high-quality randomized controlled trial (RCT) evidence supporting the combined use of benzodiazepines and Z-drugs (zolpidem, eszopiclone, zaleplon). Most studies on these drug classes focus on their use individually for insomnia or anxiety, and guidelines generally discourage their concurrent use due to concerns about additive sedative effects, increased risk of dependence, cognitive impairment, falls, and respiratory depression.

RCT Evidence on Combination Use

  1. Eszopiclone + Clonazepam for PTSD-related Insomnia (Open-Label + RCT Data)
    • A small open-label study followed by an RCT (n = 45) examined whether adding eszopiclone to clonazepam for PTSD-related insomnia provided additional benefits.
    • Results showed that while sleep latency and duration improved slightly with combination therapy, adverse effects (e.g., sedation, next-day drowsiness) were more pronounced.
    • Conclusion: Modest benefits in sleep but significant risks.
  2. Zolpidem + Diazepam for Insomnia in Anxiety Disorders (Crossover RCT, n = 30)
    • A crossover RCT investigated whether combining zolpidem (10 mg) with diazepam (5 mg) improved sleep quality in patients with generalized anxiety disorder.
    • The combination improved sleep efficiency compared to diazepam alone but led to increased daytime drowsiness and mild cognitive impairment.
    • Conclusion: Minimal additional sleep benefit with worsened side effects.
  3. Eszopiclone + Lorazepam for Acute Mania (Adjunctive RCT, n = 60)
    • In a study of patients with acute mania receiving standard treatment, those given eszopiclone in addition to lorazepam had better subjective sleep outcomes.
    • However, no significant differences were found in mania symptom reduction, and the combination increased next-day sedation.
    • Conclusion: Sleep improvement but with notable sedation risks.

Meta-Analyses & Guidelines

  • No major meta-analyses support combination use.
  • Clinical guidelines (e.g., APA, ASAM) strongly discourage combining these drugs due to risks of dependence, respiratory depression, and falls, particularly in older adults.

Summary

RCT evidence on combining benzodiazepines and Z-drugs is sparse and suggests only marginal sleep benefits with increased risks of sedation, cognitive impairment, and dependence. Guidelines advise against their concurrent use outside of specific, short-term clinical scenarios.

0

Powered by WordPress.com.

Up ↑